Lille biotekselskab fra Aarhus får 280 mio. kr. fra tunge investorer

Det blot tre år gamle NMD Pharma har netop landet en anseelig millioninvestering fra investorer som Novo Holdings, Lundbeckfonden, Roche Venture Fund og den hollandske venturefond Inkef Capital.

Photo: Colourbox

Biotekopkomlingen NMD Pharma fra Aarhus har landet 280 mio. kr. til at udvikle sin tablet mod muskelsvindssygdommen ALS.

Det skriver Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch